Despite this aspect, another clinical trial with c-kit+ cells is ongoing: indeed, the phase II CONCERT-HF (Combination of Mesenchymal and c-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure) trial aims to investigate the potential therapeutic effects of the infusion of c-kit+ cells, BM-MSCs or the combination of the two populations on patients with myocardial injury [157]. Here, KIT is linked to heart failure.